pre-IPO PHARMA

COMPANY OVERVIEW

Faze Medicines is a biotechnology company harnessing the groundbreaking new science of biomolecular condensates to create medical breakthroughs. Faze was founded by renowned scientific leaders in the field of biomolecular condensates and is supported by a world-class syndicate of investors including Third Rock Ventures, Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.fazemed.com/


    CAREER WEBSITE

    https://www.fazemed.com/the-power-of-faze/#section-3-anchor


    SOCIAL MEDIA


    INVESTORS

    abbvie-ventures alexandria-venture-investments casdin-capital catalio-capital-management eli-lilly invus novartis-venture-fund third-rock-ventures


    PRESS RELEASES


    Aug 5, 2021

    Faze Medicines Appoints New Senior Vice President, Head of People and Culture


    Dec 10, 2020

    Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease


    For More Press Releases


    Google Analytics Alternative